IDRI is home to the Global Health Vaccine Center of Innovation (GHVCI), which is focused on accelerating timelines and decreasing development costs of life-saving vaccines. The GHVCI represents an alliance among IDRI, Sanofi Pasteur and the Bill & Melinda Gates Foundation. It was founded with the goal of speeding the development of vaccines and associated technologies to fight a wide range of global infectious diseases and ensuring that these critical vaccines are accessible globally, especially to people in need within developing countries.
Each partner brings its respective expertise and technologies to the GHVCI and, collectively, the parties will collaborate with a wide range of other vaccine development organizations. Funding for the establishment, operation and growth of the GHVCI comes from Sanofi and the Gates Foundation, and additional funding will be sought to support collaborative research activities with respect to specific vaccines to be developed at the GHVCI.
This distinctive collaboration leverages the potential power of the partners’ collective expertise, combining IDRI’s vaccine design, formulation and production technologies; Sanofi’s position as a leading multi-national vaccine developer, manufacturer and seller; and the Gates Foundation’s knowledge, influence and financial support regarding the discovery and development of global health interventions, including vaccines. A key component is the application of IDRI’s vaccine adjuvant technologies and formulation expertise, which have been developed over the past few years with strong financial support from the Gates Foundation.
Members of the GHVCI joint steering committee include:
- Chris Wilson, Bill & Melinda Gates Foundation
- Chris Karp, Bill & Melinda Gates Foundation
- Jean Lang, Sanofi Pasteur
- Gavin Zealey, Sanofi Pasteur
- Steve Reed, IDRI
- Erik Iverson, IDRI
GHVCI personnel includes:
- Charles Lutsch, Sanofi Pasteur, GHVCI Research & Development Leader
- Dan Stinchcomb, IDRI, SVP for Vaccine Development & Viral Vaccine Programs
- Chris Kuehn, IDRI, Sr. Project Manager
A joint steering committee, comprised of representatives from each of the three partners, will mutually identify areas of research to discover, evaluate and develop novel human vaccines, as well as adjuvant/formulation platforms for the rapid response to emerging pathogens, that can prevent or treat infectious diseases.
We expect to soon announce the first disease projects for GHVCI.